HMHaibo Mu

Haibo Mu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haibo Mu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Fang Liu

    Department of Clinical Laboratory, Chongqing Red Cross Hospital, People’s Hospital of Jiangbei District, Chongqing 400020, China

    1 shared publication
  • Jianguo He

    Department of Neurosurgery, Chongqing Red Cross Hospital, People’s Hospital of Jiangbei District, Chongqing 400020, China

    1 shared publication
  • Jinyou Duan

    College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, Shaanxi, China

    1 shared publication
  • Lijie Huang

    Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling, 712100 Shaanxi, China

    1 shared publication
  • Lili Kong

    Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling, 712100 Shaanxi, China

    1 shared publication
  • Xiaoli Zhang

    College of Chemistry & Pharmacy, Shaanxi Key Laboratory of Natural Products & Chemical Biology, Northwest A&F University, 22 Xinong Road, Yangling, Xianyang, Shaanxi 712100, P. R. China

    1 shared publication

Latest Publications

  • Retracted
    Open Access

    The In Vitro Antimicrobial and Antibiofilm Activities of Lysozyme against Gram-Positive Bacteria

    by Fang Liu, Xing Wang, Lijie Huang, Xinling Wang, Lili Kong, Jinyou Duan, Xiaoli Zhang, Haibo Mu, Jianguo He

    Objective. To analyze the in vitro antibacterial and antibiofilm activities of lysozyme (LYS) and its combination with various drugs against Gram-positive bacteria (GPB, ), thus to provide an exploration direction for drug development. Methods. The minimum inhibitory concentrations (MICs) of linezolid (LZD), amikacin (AMK), ceftriaxone/sulbactam (CRO/SBT), cefotaxime/sulbactam (CTX/SBT), piperacillin/sulbactam (PIP/SBT), doxycycline (DOX), levofloxacin (LVX), amoxicillin/clavulanate potassium (7 : 1, AK71), imipenem (IPM), azithromycin (AZM), and their combinations with LYS were determined with tuber twice dilution. The antimicrobial and antibiofilm activities of LYS, AZM, LVX, and their combinations with others were evaluated through MTT and crystal violet assay. Results. High-dose LYS (30 μg/mL) combined with PIP/SBT and AK71, respectively, showed synergistic antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), while it showed no synergistic activities when combined with other drugs. LYS and AZM inhibited the biofilm formation of one MRSA strain, but they and LVX had no similar activities against methicillin-resistant Staphylococcus epidermidis (MRSE) or vancomycin-resistant Enterococcus faecium (VREF). Particularly, LYS increased the permeability of biofilms of MRSA 33 and exhibited antibiofilm activities against MRSA 31 ( ) and MRSE 61 ( ). The combinations of PIP/SBT+LYS, AMK+LYS, and LZD+LYS showed stronger antibiofilm activities against MRSA 62, MRSE 62, MRSE 63, and VREF 11. Conclusion. The antimicrobial and antibiofilm activities of LYS against MRSA were better than AZM, while that of LYS against MRSE and VREF, respectively, was similar with AZM and LVX.